Research progress in antibody-drug conjugate therapy for biliary tract cancer

doi:10.3877/cma.j.issn.2095-3232.2026.05.006

Abstract

Abstract:

Biliary tract cancer (BTC) is a common malignancy originating from the biliary epithelia, characterized by high heterogeneity, strong invasiveness and poor prognosis. Surgical resection remains the only radical treatment. However, 60%-80% of BTC patients are diagnosed at advanced stage upon admission, limiting surgical efficacy. In recent years, with the advancement of next-generation sequencing and the development of novel clinical drugs, immunotherapy and targeted therapy have gradually emerged as new directions in clinical treatment. Antibody-drug conjugate (ADC), with dual characteristics of "precise targeting + efficient killing," has gradually become a research hotspot in the treatment of BTC. In this article, research progress in novel ADC drugs in the treatment of BTC was reviewed.

Key words: Biliary tract neoplasm, Antibody-drug conjugate, Therapy, Targeted therapy

Liukang Tang, Mingzheng Chen, Yulong Li, Yuting Zheng, Feng Xie. Research progress in antibody-drug conjugate therapy for biliary tract cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(05): 718-723.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2026.05.006

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2026/V15/I05/718

References 45

[1]	赵海涛. 进展期胆管癌治疗探索及展望[J/OL]. 中华普通外科学文献(电子版), 2025, 19(2): 110-110.DOI: 10.3877/cma.j.issn.1674-0793.2025.02.015.
[2]	王闪闪, 赵海涛. 胆道癌转化手术策略[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(1): 1-5.DOI: 10.3877/cma.j.issn.2095-2015.2025.01.001.
[3]	Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1): 235-243.DOI: 10.1245/s10434-015-4642-9.
[4]	Alabraba E, Joshi H, Bird N, et al. Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged[J]. Eur J Surg Oncol, 2019, 45(9): 1660-1667.DOI: 10.1016/j.ejso.2019.04.002.
[5]	Konstantinidis IT. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience[J]. Arch Surg, 2009, 144(5): 441.DOI: 10.1001/archsurg.2009.46.
[6]	American Cancer Society. Survival rates for bile duct cancer[EB/OL]. [2025-12-02].
[7]	Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. Expert Rev Gastroenterol Hepatol, 2010, 4(4): 395-397.DOI: 10.1586/egh.10.45.
[8]	Vivaldi C, Fornaro L, Ugolini C, et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer[J]. Oncologist, 2020, 25(10): 886-893.DOI: 10.1634/theoncologist.2019-0922.
[9]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study[J]. J Clin Oncol, 2020, 38(17): 1887-1896.DOI: 10.1200/jco.19.02318.
[10]	Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25): 2419-2430.DOI: 10.1056/nejmoa2004413.
[11]	Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 779-789.DOI: 10.1016/s1470-2045(21)00086-3.
[12]	Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors[J]. Cancer Discov, 2020, 10(5): 688-701.DOI: 10.1158/2159-8290.cd-19-1014.
[13]	Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(1): 47-58.DOI: 10.1200/jco.23.02005.
[14]	Ohba A, Morizane C, Ueno M, et al. Multicenter phase Ⅱ trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial[J]. Future Oncol, 2022, 18(19): 2351-2360.DOI: 10.2217/fon-2022-0214.
[15]	Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(27): 3207-3217.DOI: 10.1200/jco.23.02010.
[16]	连云港经济技术开发区管理委员会. 捷报！恒瑞ADC创新药SHR-A1811 HER2阳性胆道癌适应症拟纳入突破性治疗品种公示[EB/OL]. (2024-06-24)[2025-10-02].
[17]	Keira Y, Takasawa A, Murata M, et al. An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens[J]. Virchows Arch, 2015, 466(3): 265-277.DOI: 10.1007/s00428-014-1705-4.
[18]	Shinozaki A, Shibahara J, Noda N, et al. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma[J]. Virchows Arch, 2011, 459(1): 73-80.DOI: 10.1007/s00428-011-1092-z.
[19]	Isidro RA, Abukhiran I, Dunseth CD, et al. Strong annexin A10 expression supports a pancreatic primary and combined annexin A10, claudin 18, and SOX2 expression supports an esophagogastric origin in carcinomas of unknown primary[J]. Am J Surg Pathol, 2023, 47(4): 440-452.DOI: 10.1097/pas.0000000000001994.
[20]	Kinzler MN, Gretser S, Schulze F, et al. Expression of claudin-18. 2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre[J]. Histopathology, 2025, 86(4): 640-646.DOI: 10.1111/his.15407.
[21]	Yu X, Zhang J, Tazbirkova A, et al. Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study[J]. J Clin Oncol, 2024, 42(16_suppl): 3037.DOI: 10.1200/jco.2024.42.16_suppl.3037.
[22]	Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-esophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial[J]. Lancet Oncol, 2025, 26(2): 227-238.DOI: 10.1016/s1470-2045(24)00636-3.
[23]	Gwak GY, Yoon JH, Shin CM, et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas[J]. J Cancer Res Clin Oncol, 2005, 131(10): 649-652.DOI: 10.1007/s00432-005-0016-1.
[24]	Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers[J]. J Pathol, 2005, 206(3): 356-365.DOI: 10.1002/path.1779.
[25]	Kim SB, Meric-Bernstam F, Kalyan A, et al. First-in-human phase Ⅰ study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer[J]. Target Oncol, 2019, 14(5): 591-601.DOI: 10.1007/s11523-019-00670-4.
[26]	Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma[J]. Hepatology, 2014, 59(4): 1427-1434.DOI: 10.1002/hep.26890.
[27]	Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma[J]. Hum Pathol, 2014, 45(8): 1630-1638.DOI: 10.1016/j.humpath.2014.03.014.
[28]	Maruki Y, Morizane C, Arai Y, et al. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)[J]. J Gastroenterol, 2021, 56(3): 250-260.DOI: 10.1007/s00535-020-01735-2.
[29]	Ma Y, Huang Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study[J]. Lancet Oncol, 2024, 25(7): 901-911.DOI: 10.1016/s1470-2045(24)00159-1.
[30]	Kuwatani M, Sakamoto N. Promising highly targeted therapies for cholangiocarcinoma: a review and future perspectives[J]. Cancers, 2023, 15(14): 3686.DOI: 10.3390/cancers15143686.
[31]	Yokota K, Serada S, Tsujii S, et al. Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1-positive cholangiocarcinoma[J]. Mol Cancer Ther, 2021, 20(9): 1713-1722.DOI: 10.1158/1535-7163.mct-21-0015.
[32]	Chen MB, Wu HF, Zhan Y, et al. Prognostic value of TROP2 expression in patients with gallbladder cancer[J]. Tumor Biol, 2014, 35(11): 11565-11569.DOI: 10.1007/s13277-014-2469-9.
[33]	Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer[J]. Br J Cancer, 2008, 99(8): 1290-1295.DOI: 10.1038/sj.bjc.6604677.
[34]	Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity[J]. Mod Pathol, 2008, 21(2): 186-191.DOI: 10.1038/modpathol.3801001.
[35]	Davidson D, Wang Y, Aloyz R, et al. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines[J]. Investig New Drugs, 2013, 31(2): 461-468.DOI: 10.1007/s10637-012-9886-7.
[36]	Mühlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma[J]. J Clin Pathol, 2009, 62(2): 152-158.DOI: 10.1136/jcp.2008.060590.
[37]	Zhang Y, Wang H, Overman M, et al. Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma[J]. Hum Pathol, 2023, 139: 117-125.DOI: 10.1016/j.humpath.2023.07.011.
[38]	Liu X, Ma L, Li J, et al. Trop2-targeted therapies in solid tumors: advances and future directions[J]. Theranostics, 2024, 14(9): 3674-3692.DOI: 10.7150/thno.98178.
[39]	Yang L, Guo T, Jiang S, et al. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder[J]. Hepatogastroenterology, 2012, 59(118): 1769-1775.DOI: 10.5754/hge11744.
[40]	Moon WS, Park HS, Lee H, et al. Co-expression of cox-2, C-met and β-catenin in cells forming invasive front of gallbladder cancer[J]. Cancer Res Treat, 2005, 37(3): 171.DOI: 10.4143/crt.2005.37.3.171.
[41]	Heo MH, Kim HK, Lee H, et al. The clinical impact of c-MET over-expression in advanced biliary tract cancer (BTC)[J]. J Cancer, 2017, 8(8): 1395-1399.DOI: 10.7150/jca.17898.
[42]	Sanada Y, Osada S, Tokuyama Y, et al. Critical role of c-met and Ki67 in progress of biliary carcinoma[J]. Am Surg, 2010, 76(4): 372-379.DOI: 10.1177/000313481007600413.
[43]	Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma[J]. Br J Cancer, 2011, 105(1): 131-138.DOI: 10.1038/bjc.2011.199.
[44]	Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis[J]. Hum Pathol, 1998, 29(2): 175-180.DOI: 10.1016/s0046-8177(98)90229-5.
[45]	Camidge DR, Morgensztern D, Heist RS, et al. Phase I study of 2-or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-met, monotherapy in patients with advanced non-small cell lung carcinoma[J]. Clin Cancer Res, 2021, 27(21): 5781-5792.DOI: 10.1158/1078-0432.ccr-21-0765.

Please choose a citation manager

Content to export